Cargando...
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Immune checkpoint inhibitors (ICI) have revolutionised cancer therapy. However, they have been effective in only a small subset of patients and a principal mechanism underlying immune-refractoriness is a ‘cold’ tumour microenvironment, that is, lack of a T-cell-rich, spontaneously inflamed phenotype...
Gardado en:
| Publicado en: | J Clin Med |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7602874/ https://ncbi.nlm.nih.gov/pubmed/33081170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9103323 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|